Abstract:Background: The robustness and reproducibility of transcriptomics-derived models were limited by the various microenvironmental conditions like stromal context and tumor purity. We aimed to explore a robust prognostic and immunotherapeutic predictive model by differentiating cell origins in lung adenocarcinoma (LUAD).Methods: A total of 2,451 patients in 12 independent cohorts with transcriptomic data, including 10 public datasets and two in-house cohorts, were analyzed. The tumor immune cell score (TICS) and tumor stromal score (TSCS) was developed depending on the candidate immune or stromal cells in the training meta-cohorts (n=6), and then verified in four datasets. Therapeutic responses including immune checkpoint inhibitors (ICIs), chemotherapy and tyrosine kinase inhibitor (TKI) were compared between high- and low- TICS groups in the advanced-stage LUAD.Finding: The TICS, instead of TSCS, contributed majorly for predicting clinical outcomes in LUAD. The high TICS was associated with a prolonged overall survival (OS) in the training meta-cohorts (HR 0·55, 95%CI 0·45-0·66) and was validated in three public cohorts and one in-house cohort. The prognostic efficacy of TICS was more significant in the early-stage LUAD (HR=0·49, 95%CI: 0·38-0·63). For the advanced-stage LUAD, high TICS predicted a superior OS in patients who treated with ICIs (HR 0·09, 95% CI 0·02-0·32) instead of chemotherapy (HR 0·84, 95% CI 0·30-2·30) or TKI (HR 1·20, 95% CI 0·08-20·00).Interpretation: TICS is associated with survival in patients with LUAD, and may serve as a predictor for the benefit of ICIs in advanced LUAD.Funding Information: National Natural Sciences Foundation (82102886 for JX); Beijing Nova Program (Z211100002121055 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021029 for JX); National Natural Sciences Foundation (82203827 for ZY); the Special Research Fund for Central Universities, Peking Union Medical College (3332021028 for ZY); Beijing Natural Science Foundation (7222146 for ZY); Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120); Beijing Hope Run Special Fund of Cancer Foundation of China (LC2021B22, LC2020B09, LC2020A33); the National Natural Sciences Foundation (81871889 and 82072586 for ZW) and Beijing Natural Science Foundation (7212084 for ZW).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: All patients have informed consent and this study was approved by the ethics committees of the National Cancer Center (NCC-22/250-3454, NCC-22/429-3631). Patients without follow-up information were removed from further evaluation.

Inferior vena cava diameter and central venous pressure correlation during cardiac surgery.

LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma

Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

Integrated Analysis of Single-Cell and Bulk RNA Sequencing Reveals a Malignancy-Related Signature in Lung Adenocarcinoma.

Integrated multi-omics analysis and machine learning to refine molecular subtypes, prognosis, and immunotherapy in lung adenocarcinoma

Trans-omics Biomarker Model Improves Prognostic Prediction Accuracy for Early-Stage Lung Adenocarcinoma.

Molecular subtypes and prognostic models for predicting prognosis of lung adenocarcinoma based on miRNA-related genes

A&nbsp;Novel Prognostic and Immunotherapeutic Predictive Model Based On&nbsp;cell-Originated Characterization of Tumor Microenvironment in Lung Adenocarcinoma

[Primary tumors of the operated stomach].

Development and validation of machine learning models for diagnosis and prognosis of lung adenocarcinoma, and immune infiltration analysis

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing

A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

Identifying and assessing a prognostic model based on disulfidptosis-related genes: implications for immune microenvironment and tumor biology in lung adenocarcinoma